Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475693 · ClinicalTrials.gov registry record · Early Phase 1
A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents
A Early Phase 1 study of Concussion Post Syndrome, sponsored by Corewell Health South.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03475693 is a Early Phase 1 study of Concussion Post Syndrome that has completed, run by Corewell Health South. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03475693, a Early Phase 1 study of Concussion Post Syndrome, has completed, sponsored by Corewell Health South.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy of magnesium in symptomatic reduction of mild traumatic brain injury in the adolescent population in the acute setting of injury.
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Magnesium Oxide
- DRUG Zofran ODT 4 MG Disintegrating Oral Tablet
Study Locations (1)
Michigan
- Lakeland Regional Healthcare - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2019-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03475693
The ClinicalTrials.gov registry entry for NCT03475693 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health South, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Concussion Post Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Acetaminophen is the first listed.
NCT03475693 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03475693 about?
NCT03475693 is a clinical study titled "A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents". The objective of this study is to evaluate the efficacy of magnesium in symptomatic reduction of mild traumatic brain injury in the adolescent population in the acute setting of injury.
What is the current status of trial NCT03475693?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2017-09-01. Estimated completion is 2019-12-30.
What conditions does trial NCT03475693 study?
This clinical trial studies the following conditions: Concussion Post Syndrome.
What interventions are being tested in trial NCT03475693?
The interventions under investigation include: Acetaminophen (DRUG), Magnesium Oxide (DRUG), Zofran ODT 4 MG Disintegrating Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03475693?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03475693 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.